Top 10 Companies in the (R)-(-)-2-Phenylbutyric Acid (CAS 938-79-4) Market (2026): Market Leaders Powering Global Pharmaceutical Innovation

MARKET INSIGHTS

Global (R)-(-)-2-Phenylbutyric Acid (CAS 938-79-4) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 6.4% during the forecast period.

(R)-(-)-2-Phenylbutyric Acid (CAS 938-79-4) is a chiral carboxylic acid derivative characterized by its specific optical rotation and (R)-configuration at the stereocenter. It serves as a critical chiral building block and intermediate in the synthesis of pharmaceuticals, agrochemicals, and fine chemical compounds, where stereochemical precision is essential to achieving desired biological activity and regulatory compliance.

The market is steadily expanding, driven primarily by rising demand for enantiopure intermediates in pharmaceutical manufacturing and the growing emphasis on asymmetric synthesis in drug development pipelines. Furthermore, increasing regulatory scrutiny over racemic drug formulations has encouraged manufacturers to adopt chiral-specific raw materials, directly benefiting demand for compounds such as (R)-(-)-2-Phenylbutyric Acid. Key producers operating in this space include established fine chemical and chiral chemistry suppliers serving global pharmaceutical and agrochemical industries.

(R)-(-)-2-Phenylbutyric Acid (CAS 938-79-4) Market – View in Detailed Research Report

🔟 1. Merck KGaA

Headquarters: Darmstadt, Germany

Key Offering: Pharmaceutical‑grade chiral intermediates and API building blocks.

Merck KGaA leverages its integrated R&D and manufacturing footprint to supply high‑purity (R)-(-)-2‑Phenylbutyric Acid to major pharma OEMs. Its extensive portfolio of asymmetric synthesis technologies ensures consistent supply of enantiomerically pure compounds.

Sustainability Initiatives:

• Investment in green chemistry and renewable energy for production facilities.
• Partnerships with pharma clients to develop sustainable supply chains.
• Commitment to net‑zero emissions across operations by 2030.

9️⃣ 2. Tokyo Chemical Industry Co., Ltd. (TCI)

Headquarters: Tokyo, Japan

Key Offering: Proprietary asymmetric synthesis and chiral resolution technologies.

TCI excels in delivering high‑quality chiral intermediates with over 99% enantiomeric excess, supporting the development of single‑isomer drugs and agrochemical applications.

Sustainability Initiatives:

• Continuous improvement of catalytic processes to reduce waste.
• Development of biocatalytic routes for lower environmental impact.
• Engagement in global sustainability programs and ESG reporting.

8️⃣ 3. Cayman Chemical Company

Headquarters: Burlington, Vermont, USA

Key Offering: Custom synthesis and high‑purity chiral reagents.

The company provides tailored solutions for R&D labs and small‑to‑medium manufacturers, focusing on flexibility and rapid turnaround.

Sustainability Initiatives:

• Adoption of solvent‑free and aqueous synthesis protocols.
• Use of recyclable catalysts and greener reagents.
• Commitment to reducing carbon footprint of production.

7️⃣ 4. Biosynth

Headquarters: Basel, Switzerland

Key Offering: Custom synthesis of rare chirals and scalable production services.

Biosynth differentiates itself through rapid delivery and advanced process development for complex chiral molecules, catering to both pharma and fine‑chemical markets.

Sustainability Initiatives:

• Investment in enzymatic synthesis platforms.
• Partnerships with academic institutions for green chemistry research.
• Reduction of hazardous waste through process optimization.

6️⃣ 5. Apollo Scientific Ltd.

Headquarters: London, United Kingdom

Key Offering: Rapid custom synthesis and analytical support for chiral intermediates.

Apollo Scientific provides high‑quality chiral reagents to R&D labs and contract manufacturers, emphasizing speed and technical support.

Sustainability Initiatives:

• Implementation of green chemistry guidelines in synthesis protocols.
• Energy‑efficient manufacturing practices.
• Transparent reporting of environmental metrics.

5️⃣ 6. SynQuest Laboratories, Inc.

Headquarters: San Diego, California, USA

Key Offering: Custom synthesis and analytical services for chiral intermediates.

SynQuest offers end‑to‑end solutions for small‑batch production, supporting early‑stage drug discovery and fine‑chemical development.

Sustainability Initiatives:

• Adoption of solvent‑reduced processes.
• Use of renewable feedstocks where feasible.
• Commitment to ISO 14001 environmental management.

4️⃣ 7. Hairui Fine Chemicals

Headquarters: Shanghai, China

Key Offering: Large‑scale production of pharmaceutical‑grade chiral intermediates.

Hairui Fine Chemicals has expanded capacity through strategic investments, focusing on cost‑effective and scalable production of (R)-(-)-2‑Phenylbutyric Acid.

Sustainability Initiatives:

• Investment in green chemistry routes and waste minimization.
• Energy‑efficient manufacturing processes.
• Collaboration with local partners for sustainable supply chains.

3️⃣ 8. Finetech Industry Limited

Headquarters: Shenzhen, China

Key Offering: High‑purity chiral intermediates and custom synthesis.

Finetech focuses on advanced asymmetric catalysis and process optimization to deliver cost‑competitive chiral compounds.

Sustainability Initiatives:

• Implementation of biocatalytic processes.
• Reduction of hazardous solvent usage.
• Engagement in corporate sustainability reporting.

2️⃣ 9. Capot Chemical Co., Ltd.

Headquarters: Guangzhou, China

Key Offering: Pharmaceutical‑grade chiral building blocks.

Capot Chemical serves the growing demand for enantiopure intermediates in the Asian pharmaceutical market, leveraging local manufacturing advantages.

Sustainability Initiatives:

• Adoption of greener synthesis routes.
• Energy‑saving manufacturing technologies.
• Compliance with international environmental standards.

1️⃣ 10. Chem‑Impex International, Inc.

Headquarters: New York, New York, USA

Key Offering: Custom synthesis and analytical support for chiral intermediates.

Chem‑Impex provides high‑quality chiral reagents to academic and industrial R&D, emphasizing technical expertise and rapid delivery.

Sustainability Initiatives:

• Use of renewable energy in production facilities.
• Implementation of green chemistry best practices.
• Transparent reporting of environmental impact.

Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/307455/phenylbutyric-acid-market

Get Full Report: https://www.24chemicalresearch.com/reports/307455/phenylbutyric-acid-market

Outlook: The Future of (R)-(-)-2-Phenylbutyric Acid Market

With a projected CAGR of 6.4% through 2034, the market is poised for steady growth driven by expanding pharmaceutical pipelines, regulatory emphasis on chiral purity, and advancements in asymmetric synthesis technologies. Key growth areas include precision medicine, CNS therapeutics, and sustainable manufacturing.

• Expansion of chiral API production in emerging markets.
• Adoption of biocatalytic processes reducing cost and environmental impact.
• Increased investment in R&D for next‑generation chiral acids.

Future Trends: Emerging Opportunities and Challenges

Emerging trends are reshaping the market landscape. Regulatory scrutiny over racemic drugs is intensifying, driving demand for chiral intermediates. Supply chain regionalization is shifting production to Asia‑Pacific hubs, while sustainability initiatives are driving adoption of green chemistry routes.

• Rise of sustainable manufacturing and ESG compliance.
• Technology‑driven cost reductions through enzymatic synthesis.
• Potential regulatory barriers due to intellectual property constraints.